Reality Check on Metastatic Prostate Cancer
Market access for metastatic prostate cancer treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.
To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:
- Payer Insights: Under the pharmacy benefit, almost 56% of the lives under commercial formularies are covered with utilization management restrictions
- Class Trends: Although poly (ADP-ribose) polymerase (PARP) inhibitors are not new to the market, two of them — AstraZeneca and Merck & Co., Inc.’s Lynparza (olaparib) and Clovis Oncology, Inc.’s Rubraca (rucaparib) — gained approval for use in prostate cancer for the first time in 2020. The therapies will bring a new option for the treatment of certain subpopulations of patients
- Key Findings: The products in this indication are well-reimbursed by payers. Pharmacy and medical policies may require procurement of a drug through a specialty pharmacy by either the patient or the administering doctor
What can pharma do to curb this trend and overcome these challenges?
Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.
Download the full Reality Check now.